Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

First gene therapy for β-thalassemia approved

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Biotechnology 37, 1102-1103 (2019)


Updates & Corrections

  • Correction 03 June 2020: The version of this article originally published online stated that transfusion requirements were reduced in three out of nine adult participants in the OTL-300 trial. In fact, they were reduced in all three adult participants. The error has been corrected in the print, PDF and HTML versions of this article.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links